• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者报告的通过初级保健网络提供的群体遗传检测的结果和体验。

Patient-Reported Outcomes and Experiences with Population Genetic Testing Offered Through a Primary Care Network.

机构信息

Neaman Center for Personalized Medicine, NorthShore University HealthSystem, Evanston, Illinois, USA.

Division of Medical Genetics, University of Washington, Seattle, Washington, USA.

出版信息

Genet Test Mol Biomarkers. 2021 Feb;25(2):152-160. doi: 10.1089/gtmb.2020.0275.

DOI:10.1089/gtmb.2020.0275
PMID:33596141
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7891215/
Abstract

To explore patient experiences in a large-scale primary care-based, preemptive genetic testing program. Patients who received genetic results from the initiative were invited to participate in an online survey 3 weeks postresult disclosure. A 6-month follow-up survey was sent to assess changes over time. The initial survey was completed by 1646 patients, with 544 completing the 6-month follow-up survey. The following outcomes were high overall: patient-reported understanding of results (cancer: 87%; cardiac: 86%); perceived utility (75%); positive emotions (relieved: 66.8%; happy: 62.0%); family result sharing (67.6%); and satisfaction (87%), although analysis by demographic factors identified groups who may benefit from additional education and emotional support. Results-related health behaviors and discussions with providers increased over time (screening procedures 6.1% to 14.2%  < 0.001; provider discussion 10.3% to 25.3%,  < 0.001), and were more likely to take place for patients with positive cancer and/or cardiac results (39.8% vs. 7.6%,  < 0.001). Forty-seven percent of patients reported insurance discrimination concerns, and most (79.4%) were not familiar with privacy and nondiscrimination laws. Concerns regarding discrimination and negative emotions decreased between the two survey time points (privacy issues 44.6% to 35.1%  < 0.001; life insurance discrimination concerns 35.5% to 29.6%,  = 0.001; anxiety 8.1% to 3.3%,  < 0.001; and uncertainty 19.8% to 12.8%,  < 0.001). These findings led to the development and integration of additional patient resources to improve program implementation. Our findings highlight patient experiences with and areas of need in a community-based genomic screening pilot initiative using a mixed primary care/genetics provider model to deliver precision medicine.

摘要

探索在大规模基于初级保健的预防性基因检测计划中患者的体验。 从该计划中获得基因检测结果的患者被邀请参与在线调查,调查在结果披露后 3 周进行。在 6 个月时进行后续调查,以评估随时间的变化。 初始调查完成了 1646 名患者,其中 544 名完成了 6 个月的后续调查。以下结果总体较高:患者对结果的报告理解(癌症:87%;心脏:86%);感知效用(75%);积极情绪(缓解:66.8%;高兴:62.0%);家庭结果分享(67.6%);满意度(87%),尽管按人口统计学因素进行分析发现,一些患者可能需要额外的教育和情感支持。与结果相关的健康行为和与提供者的讨论随时间增加(筛查程序从 6.1%增加到 14.2%, <0.001;提供者讨论从 10.3%增加到 25.3%, <0.001),并且更有可能发生在癌症和/或心脏阳性结果的患者中(39.8%对 7.6%, <0.001)。47%的患者报告存在保险歧视问题,并且大多数(79.4%)不了解隐私和非歧视法律。在两次调查时间点之间,对歧视和负面情绪的担忧有所减少(隐私问题从 44.6%降至 35.1%, <0.001;人寿保险歧视问题从 35.5%降至 29.6%, =0.001;焦虑从 8.1%降至 3.3%, <0.001;和不确定性从 19.8%降至 12.8%, <0.001)。这些发现导致开发和整合了更多的患者资源,以改善计划的实施。 我们的研究结果突出了在使用初级保健/遗传学提供者混合模式提供精准医学的基于社区的基因组筛查试点计划中患者的体验和需求领域。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/8c2ad68975b8/gtmb.2020.0275_figure6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/936a51157938/gtmb.2020.0275_figure1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/1ea522cb91fe/gtmb.2020.0275_figure2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/f6547ce41a4f/gtmb.2020.0275_figure3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/c7c515c8b068/gtmb.2020.0275_figure4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/a3e646c7a383/gtmb.2020.0275_figure5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/8c2ad68975b8/gtmb.2020.0275_figure6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/936a51157938/gtmb.2020.0275_figure1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/1ea522cb91fe/gtmb.2020.0275_figure2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/f6547ce41a4f/gtmb.2020.0275_figure3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/c7c515c8b068/gtmb.2020.0275_figure4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/a3e646c7a383/gtmb.2020.0275_figure5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/093a/7891215/8c2ad68975b8/gtmb.2020.0275_figure6.jpg

相似文献

1
Patient-Reported Outcomes and Experiences with Population Genetic Testing Offered Through a Primary Care Network.患者报告的通过初级保健网络提供的群体遗传检测的结果和体验。
Genet Test Mol Biomarkers. 2021 Feb;25(2):152-160. doi: 10.1089/gtmb.2020.0275.
2
Patient perspectives following pharmacogenomics results disclosure in an integrated health system.综合医疗系统中药物基因组学检测结果披露后的患者观点
Pharmacogenomics. 2018 Mar;19(4):321-331. doi: 10.2217/pgs-2017-0191. Epub 2018 Feb 22.
3
Primary Care Physician Experiences with Integrated Population-Scale Genetic Testing: A Mixed-Methods Assessment.基层医疗医生在人群规模综合基因检测方面的经验:一项混合方法评估
J Pers Med. 2020 Oct 13;10(4):165. doi: 10.3390/jpm10040165.
4
Implementation outcomes of Humanwide: integrated precision health in team-based family practice primary care.Humanwide:基于团队的家庭实践初级保健中的综合精准健康实施结果。
BMC Fam Pract. 2021 Feb 2;22(1):28. doi: 10.1186/s12875-021-01373-4.
5
Health care professionals' attitudes towards population-based genetic testing and risk-stratification for ovarian cancer: a cross-sectional survey.医疗保健专业人员对基于人群的卵巢癌基因检测和风险分层的态度:一项横断面调查。
BMC Womens Health. 2017 Dec 16;17(1):132. doi: 10.1186/s12905-017-0488-6.
6
Evolving perspectives on genetic discrimination in health insurance among health care providers.医疗服务提供者对健康保险中基因歧视的不断变化的看法。
Fam Cancer. 2010 Jun;9(2):253-60. doi: 10.1007/s10689-009-9308-y.
7
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.美国临床肿瘤学会政策声明更新:癌症易感性基因检测
J Clin Oncol. 2003 Jun 15;21(12):2397-406. doi: 10.1200/JCO.2003.03.189. Epub 2003 Apr 11.
8
Exploring Genetic Testing for Rare Disorders of Obesity: Experience and Perspectives of Pediatric Weight Management Providers.探索肥胖罕见疾病的基因检测:儿科体重管理提供者的经验和观点。
Child Obes. 2024 Oct;20(7):451-458. doi: 10.1089/chi.2023.0125. Epub 2024 Jan 8.
9
Evaluation of a novel electronic genetic screening and clinical decision support tool in prenatal clinical settings.新型电子基因筛查与临床决策支持工具在产前临床环境中的评估
Matern Child Health J. 2014 Jul;18(5):1233-45. doi: 10.1007/s10995-013-1358-y.
10
eHealth System for Collecting and Utilizing Patient Reported Outcome Measures for Personalized Treatment and Care (PROMPT-Care) Among Cancer Patients: Mixed Methods Approach to Evaluate Feasibility and Acceptability.癌症患者中用于个性化治疗和护理的患者报告结局测量收集与利用电子健康系统(PROMPT-Care):评估可行性和可接受性的混合方法
J Med Internet Res. 2017 Oct 2;19(10):e330. doi: 10.2196/jmir.8360.

引用本文的文献

1
Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates.阿拉伯联合酋长国心血管疾病患者对药物基因组学的认知与看法
Clin Transl Sci. 2025 Aug;18(8):e70300. doi: 10.1111/cts.70300.
2
Geno4ME Study: implementation of whole genome sequencing for population screening in a large healthcare system.Geno4ME研究:在大型医疗保健系统中实施全基因组测序用于人群筛查。
NPJ Genom Med. 2025 Jul 1;10(1):50. doi: 10.1038/s41525-025-00508-1.
3
Patients' Concerns About Receiving Preemptive Pharmacogenomic Testing: Results from a Large, Longitudinal Survey of RIGHT Study Participants.

本文引用的文献

1
Primary Care Physician Experiences with Integrated Population-Scale Genetic Testing: A Mixed-Methods Assessment.基层医疗医生在人群规模综合基因检测方面的经验:一项混合方法评估
J Pers Med. 2020 Oct 13;10(4):165. doi: 10.3390/jpm10040165.
2
Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing.量化基因组检测研究中的下游医疗利用情况。
Value Health. 2020 May;23(5):559-565. doi: 10.1016/j.jval.2020.01.017. Epub 2020 Mar 20.
3
Returning Results in the Genomic Era: Initial Experiences of the eMERGE Network.基因组时代的结果反馈:eMERGE网络的初步经验
患者对接受前瞻性药物基因组检测的担忧:来自RIGHT研究参与者的大型纵向调查结果
J Pers Med. 2025 Jun 17;15(6):258. doi: 10.3390/jpm15060258.
4
Workplace perk or pitfall? A qualitative study of genetic counselors' perspectives and experiences with workplace genetic testing.职场福利还是陷阱?一项关于遗传咨询师对职场基因检测的看法和经历的定性研究。
J Genet Couns. 2025 Jun;34(3):e70016. doi: 10.1002/jgc4.70016.
5
Experiences of participants with undiagnosed diseases and hereditary cancers during the initial phase of the Hong Kong genome project: a mixed-methods study.香港基因组计划初始阶段未确诊疾病和遗传性癌症参与者的经历:一项混合方法研究
Hum Genomics. 2025 Apr 5;19(1):36. doi: 10.1186/s40246-025-00746-5.
6
Revolutionising Cardio-Oncology Care with Precision Genomics.精准基因组学彻底变革心血管肿瘤学护理
Int J Mol Sci. 2025 Feb 26;26(5):2052. doi: 10.3390/ijms26052052.
7
Experiences across a genetic screening and testing programme pathway: a qualitative study of mammogram patient perspectives.遗传筛查和检测计划路径中的体验:对乳房 X 光照片患者观点的定性研究。
BMJ Open. 2024 Oct 23;14(10):e089884. doi: 10.1136/bmjopen-2024-089884.
8
The Landscape of Genomic Services for Inherited Retinal Degenerations (IRDs) Across Europe.欧洲遗传性视网膜疾病(IRD)的基因组服务概况
Clin Ophthalmol. 2024 Aug 7;18:2217-2224. doi: 10.2147/OPTH.S465930. eCollection 2024.
9
Attitudes, knowledge, and risk perceptions of patients who received elective genomic testing as a clinical service.接受临床服务的选择性基因组检测患者的态度、知识和风险认知。
Genet Med. 2024 Oct;26(10):101200. doi: 10.1016/j.gim.2024.101200. Epub 2024 Jun 26.
10
Patient experiences and perceived value of genetic testing in inherited retinal diseases: a cross-sectional survey.遗传性视网膜疾病中基因检测的患者体验和感知价值:一项横断面调查。
Sci Rep. 2024 Mar 5;14(1):5403. doi: 10.1038/s41598-024-56121-2.
J Pers Med. 2020 Apr 27;10(2):30. doi: 10.3390/jpm10020030.
4
Assessing the implications of positive genomic screening results.评估基因组筛查阳性结果的影响。
Per Med. 2020 Mar;17(2):101-109. doi: 10.2217/pme-2019-0067. Epub 2020 Mar 3.
5
Genetic Testing: Consent and Result Disclosure for Primary Care Providers.遗传检测:初级保健提供者的同意和结果披露。
Med Clin North Am. 2019 Nov;103(6):967-976. doi: 10.1016/j.mcna.2019.07.001. Epub 2019 Aug 20.
6
Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study.临床外显子组测序与常规护理在遗传性结直肠癌诊断中的比较效果研究。
Contemp Clin Trials. 2019 Sep;84:105820. doi: 10.1016/j.cct.2019.105820. Epub 2019 Aug 7.
7
Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies.外显子组和基因组测序结果披露相关的心理结果:七项临床测序探索性研究(CSER)联盟研究的荟萃分析。
Genet Med. 2019 Dec;21(12):2781-2790. doi: 10.1038/s41436-019-0565-3. Epub 2019 Jun 13.
8
The REDCap consortium: Building an international community of software platform partners.REDCap 联盟:构建软件平台合作伙伴的国际社区。
J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016/j.jbi.2019.103208. Epub 2019 May 9.
9
The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation.基因组检测结果感受(FACToR)问卷:编制与初步验证
J Genet Couns. 2019 Apr;28(2):477-490. doi: 10.1007/s10897-018-0286-9. Epub 2018 Dec 14.
10
Much ado about nothing: A qualitative study of the experiences of an average-risk population receiving results of exome sequencing.无事生非:一项关于低风险人群接受外显子组测序结果体验的定性研究。
J Genet Couns. 2019 Apr;28(2):428-437. doi: 10.1002/jgc4.1096. Epub 2019 Mar 5.